Eli Lilly and Company (ETR: LLY)
Germany
· Delayed Price · Currency is EUR
764.20
+33.50 (4.58%)
Dec 20, 2024, 5:36 PM CET
Eli Lilly and Company Revenue
Eli Lilly and Company had revenue of $11.44B USD in the quarter ending September 30, 2024, with 20.43% growth. This brings the company's revenue in the last twelve months to $40.86B, up 27.41% year-over-year. In the year 2023, Eli Lilly and Company had annual revenue of $34.12B with 19.56% growth.
Revenue (ttm)
$40.86B
Revenue Growth
+27.41%
P/S Ratio
n/a
Revenue / Employee
$950.31K
Employees
43,000
Market Cap
663.66B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | 22.32B | 826.20M | 3.84% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEli Lilly and Company News
- 14 hours ago - FDA approves weight-loss drug to treat sleep apnea - The Hill
- 1 day ago - Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive? - Investor's Business Daily
- 1 day ago - Eli Lilly given green light in US to treat sleep disorder with weight-loss drug - Financial Times
- 1 day ago - Zepbound Approved For Sleep Apnea - Forbes
- 1 day ago - Eli Lilly's Zepbound gains sleep apnea indication - Seeking Alpha
- 1 day ago - FDA approves weight loss drug Zepbound for sleep apnea - NBC News
- 1 day ago - Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea - Reuters
- 1 day ago - FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC